FXIII-Inhibitors

Ac-(D)-Asp-MA-Nle-Nle-Leu-Pro-Trp-Pro-OH, "ZED1301"



Order
Quantity
Price
Status
5 mg 480 € available


Documents
Art. No. A108
Synonym ZED1301
Background info Peptidic inhibitor containing an electrophilic Michael acceptor (MA) warhead
Molecular Formula C53H77N9O14
Molecular Weight 1064.23
Purity by HPLC >95 % (214 nm)
Appearance Pale yellow solid
Solubility 3.50 mg/ml (3.28 mM) in PBS buffer
Alternative 10 μM in 0.1% (v/v) DMSO / aqueous buffers
Pre-dissolve e.g. 2.15 mg (2.02 μmol) in 202 μl DMSO - dilute e.g. 10 μl of that stock solution (10 mM) with 9990 μl aqueous buffer to obtain a 10 μM solution. DMSO stock solutions can be stored at -20°C for at least 6 months.
To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Application Site specific irreversible inhibitor of plasma transglutaminase (factor XIII, FXIII)
ZED1301 shows 30-fold selectivity for FXIII compared to tissue transglutaminase
IC50 = 100 nM (FXIII, using fluorescent Assay Substance A101[1])
IC50 = 3000 nM (TG2, using fluorescent Assay Substance A101[1])
[1] Oertel et al. Anal. Biochem. 2007, 367, 152.
Reference(s) Stieler, M. et al. Angewandte Chemie Intl. Ed. 2013, 52, 11930.
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events  

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy